The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier)

[1]  B. Miller,et al.  Multicenter validation of a bedside antisaccade task as a measure of executive function , 2012, Neurology.

[2]  C. Jack,et al.  Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatment trials. , 2012, Parkinsonism & related disorders.

[3]  Janet Woodcock,et al.  Accelerating identification and regulatory approval of investigational cancer drugs. , 2011, JAMA.

[4]  J. Kornak,et al.  Amyloid Vs Fdg-pet in the Differential Diagnosis of Ad And , 2022 .

[5]  Bruce L. Miller,et al.  Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS , 2011, Neuron.

[6]  Jonathan J. Evans,et al.  A systematic review of the accuracy and clinical utility of the Addenbrooke's Cognitive Examination and the Addenbrooke's Cognitive Examination—Revised in the diagnosis of dementia , 2011, International journal of geriatric psychiatry.

[7]  Nick C Fox,et al.  Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.

[8]  A. Kertesz,et al.  The effects of oxytocin on social cognition and behaviour in frontotemporal dementia. , 2011, Brain : a journal of neurology.

[9]  Albert C. Ludolph,et al.  Disease Severity and Progression in Progressive Supranuclear Palsy and Multiple System Atrophy: Validation of the NNIPPS – PARKINSON PLUS SCALE , 2011, PloS one.

[10]  J. Gunter,et al.  Trajectories of brain and hippocampal atrophy in FTD with mutations in MAPT or GRN , 2011, Neurology.

[11]  D. Galimberti,et al.  Faculty Opinions recommendation of Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia. , 2011 .

[12]  M. Cudkowicz,et al.  Emerging targets and treatments in amyotrophic lateral sclerosis , 2011, The Lancet Neurology.

[13]  Zhinan Yin,et al.  The Growth Factor Progranulin Binds to TNF Receptors and Is Therapeutic Against Inflammatory Arthritis in Mice , 2011, Science.

[14]  J. Hodges,et al.  Screening for Cognitive Dysfunction in Corticobasal Syndrome: Utility of Addenbrooke’s Cognitive Examination , 2011, Dementia and Geriatric Cognitive Disorders.

[15]  B. Miller,et al.  Classification of primary progressive aphasia and its variants , 2011, Neurology.

[16]  K. Sleegers,et al.  Rescue of Progranulin Deficiency Associated with Frontotemporal Lobar Degeneration by Alkalizing Reagents and Inhibition of Vacuolar ATPase , 2011, The Journal of Neuroscience.

[17]  Philip S. Insel,et al.  Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. , 2011, Archives of neurology.

[18]  Chengjie Xiong,et al.  Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease , 2011, Alzheimer's Research & Therapy.

[19]  J. Garre-Olmo,et al.  Incidence and subtypes of early-onset dementia in a geographically defined general population , 2010, Neurology.

[20]  T. Coté,et al.  The Impact of the Orphan Drug Act on the Development and Advancement of Neurological Products for Rare Diseases: A Descriptive Review , 2010, Clinical pharmacology and therapy.

[21]  J. Trojanowski,et al.  Novel CSF biomarkers for frontotemporal lobar degenerations , 2010, Alzheimer's & Dementia.

[22]  W. Oertel,et al.  Rational therapeutic approaches to progressive supranuclear palsy. , 2010, Brain : a journal of neurology.

[23]  M. Hornberger,et al.  Clinical Staging and Disease Progression in Frontotemporal Dementia Supplemental Data at Www.neurology.org , 2022 .

[24]  Nick C Fox,et al.  Measuring disease progression in frontotemporal lobar degeneration , 2010, Neurology.

[25]  J. Neuhaus,et al.  Off-Label Medication Use in Frontotemporal Dementia , 2010, American journal of Alzheimer's disease and other dementias.

[26]  Eric B Larson,et al.  Late-life dementias: does this unyielding global challenge require a broader view? , 2009, JAMA.

[27]  K. Romero,et al.  The Coalition Against Major Diseases: Developing Tools for an Integrated Drug Development Process for Alzheimer's and Parkinson's Diseases , 2009, Clinical pharmacology and therapeutics.

[28]  J. Trojanowski,et al.  Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies , 2009, Nature Reviews Drug Discovery.

[29]  M. Freedman,et al.  Apathy symptom profile and behavioral associations in frontotemporal dementia vs dementia of Alzheimer type. , 2009, Archives of neurology.

[30]  J. Neuhaus,et al.  An Open-label Study of Memantine Treatment in 3 Subtypes of Frontotemporal Lobar Degeneration , 2009, Alzheimer disease and associated disorders.

[31]  B. L. Miller,et al.  Brain and ventricular volumetric changes in frontotemporal lobar degeneration over 1 year , 2009, Neurology.

[32]  R. Petersen,et al.  Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members , 2009, Brain : a journal of neurology.

[33]  H. Akiyama,et al.  Phosphorylated TDP-43 in Alzheimer’s disease and dementia with Lewy bodies , 2009, Acta Neuropathologica.

[34]  John R Hodges,et al.  Activities of Daily Living in Behavioral Variant Frontotemporal Dementia: Differences in Caregiver and Performance-based Assessments , 2009, Alzheimer disease and associated disorders.

[35]  Y. Agid,et al.  Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study , 2008, Brain : a journal of neurology.

[36]  J R Hodges,et al.  Incidence of early-onset dementias in Cambridgeshire, United Kingdom , 2008, Neurology.

[37]  Nathaniel Mercaldo,et al.  Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. , 2008, Brain : a journal of neurology.

[38]  Peter Heutink,et al.  Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia , 2008, The Lancet Neurology.

[39]  C. Schade-Brittinger,et al.  Short‐term effects of coenzyme Q10 in progressive supranuclear palsy: A randomized, placebo‐controlled trial , 2008, Movement disorders : official journal of the Movement Disorder Society.

[40]  P. Uhlir,et al.  Pathways across the valley of death: novel intellectual property strategies for accelerated drug discovery. , 2008, Yale journal of health policy, law, and ethics.

[41]  A. Kertesz,et al.  Galantamine in Frontotemporal Dementia and Primary Progressive Aphasia , 2008, Dementia and Geriatric Cognitive Disorders.

[42]  David A. Bennett,et al.  Mixed brain pathologies account for most dementia cases in community-dwelling older persons , 2007, Neurology.

[43]  R. Barker,et al.  The utility of the Cambridge Behavioural Inventory in neurodegenerative disease , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[44]  J. Grace,et al.  The Frontal Systems Behavior Scale discriminates frontotemporal dementia from Alzheimer’s disease , 2007, Alzheimer's & Dementia.

[45]  J R Hodges,et al.  Activities of daily living in frontotemporal dementia and Alzheimer disease , 2007, Neurology.

[46]  L. Golbe,et al.  A clinical rating scale for progressive supranuclear palsy. , 2007, Brain : a journal of neurology.

[47]  Clifford R Jack,et al.  Rates of cerebral atrophy differ in different degenerative pathologies. , 2006, Brain : a journal of neurology.

[48]  John R Hodges,et al.  The Addenbrooke's Cognitive Examination Revised (ACE‐R): a brief cognitive test battery for dementia screening , 2006, International journal of geriatric psychiatry.

[49]  Jordan Grafman,et al.  A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia , 2006, Neurology.

[50]  K Yaffe,et al.  Frontotemporal dementia progresses to death faster than Alzheimer disease , 2005, Neurology.

[51]  C. DeCarli,et al.  Rate of progression differs in frontotemporal dementia and Alzheimer disease , 2005, Neurology.

[52]  Jennifer Farmer,et al.  Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease , 2005, Annals of neurology.

[53]  F. Pasquier,et al.  Frontotemporal Dementia: A Randomised, Controlled Trial with Trazodone , 2004, Dementia and Geriatric Cognitive Disorders.

[54]  B. Sahakian,et al.  Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial , 2004, Psychopharmacology.

[55]  R. Petersen,et al.  The incidence of frontotemporal lobar degeneration in Rochester, Minnesota, 1990 through 1994 , 2004, Neurology.

[56]  A. Bava,et al.  Frontotemporal Dementia: Paroxetine as a Possible Treatment of Behavior Symptoms , 2002, European Neurology.

[57]  J R Hodges,et al.  The prevalence of frontotemporal dementia , 2002, Neurology.

[58]  M. Hallett,et al.  Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy , 2001, Neurology.

[59]  D. Burn,et al.  The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. , 2001, Brain : a journal of neurology.

[60]  P. S. Mathuranath,et al.  A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia , 2000, Neurology.

[61]  A. Kertesz,et al.  Frontal Behavioral Inventory: Diagnostic Criteria for Frontal Lobe Dementi , 1997, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[62]  M. Hallett,et al.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.

[63]  L. Golbe,et al.  Prevalence and natural history of progressive supranuclear palsy , 1988, Neurology.

[64]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[65]  C. Volteau,et al.  Memantine in behavioral variant frontotemporal dementia: negative results. , 2011, Journal of Alzheimer's disease : JAD.

[66]  J. Trojanowski,et al.  Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations , 2008, Acta Neuropathologica.